Abstract
Gastrointestinal myoelectrical activity (GIMA) biomarkers, measured by the Electroviscerography-based EndoSure device, have shown significant diagnostic capabilities. This study aimed to validate EndoSure for detecting endometriosis and distinguishing between subjects with and without biopsy proven endometriosis.
Endometriotic lesions secrete prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α), which generate distinctive motility patterns in small bowel smooth muscle, leading to elevated gastrointestinal myoelectrical energy (GIMA). EndoSure is a non-invasive, 30-minute clinical test designed to detect these patterns. Patients in two gynecological and gastrointestinal referral practices were randomly selected and prospectively offered EndoSure testing (EVG). Subjects had known histories of having either biopsy confirmed endometriosis or an absence of disease. The EVG technicians and physicians analyzing the EVG studies were blinded to clinical data.
Three hundred forty (340) female patients were enrolled between December 2024 and May 2025. The mean age was 38 years with an age range 9-81and mean BMI was 24.2 kg/m² (SD ±9.0). Of these, 54 were excluded due to incomplete data, leaving 286 evaluable subjects. All underwent record review and EVG. EndoSure demonstrated a sensitivity of 94.7% and specificity of 85.48% with NPV/PPV of 98.7/51.08 and diagnostic accuracy of 91.5% for detecting superficial, deep and ovarian endometriosis and selecting patients without disease. Of the 286 subjects, 233 had documented endometriosis and 53 were known to be disease free.
GIMA biomarkers represent a promising new primary screening tool for patients with suspected endometriosis. Further research is warranted to further validate the test and demonstrate it may improve resource utilization and management in patients with superficial endometriosis.


